Press Release
Biosimilar Basics for Oncology Nurses and Patients
“The way I approach patient education conversations is to discuss it, address it, but not to emphasize it. I really like to focus on what the drug is. I mention if it’s a biosimilar, I explain it, I give resources if they want it, but I really try to focus on the things that they’re going to need to know in order to help be part of their care, but have readily available information to give them if they want more,” ONS affiliate member Rowena (Moe) Schwartz, PharmD, BCOP, professor of pharmacy practice at the University of Cincinnati in Ohio, told Jaime Weimer, MSN, RN, AGCNS-BC, AOCNS®, oncology clinical specialist at ONS during a discussion about the basics of biosimilars for nurses and patients.
Related Topics
You May Also Like
Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
Press Release
Introducing OncologyVoiceNetwork.com
Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
Podcast